Fig. 5.

WYC-209 inhibits tumor metastasis in vivo. a Schematic of the experimental protocol; i.v., intravenous injection. Control B16-F1 cells were cultured in 90-Pa fibrin gels for 5 days to form TRCs. TRCs were isolated from gels and injected intravenously via tail veins into wild-type immune-competent syngeneic C57BL/6 mice at 30,000 cells per mouse. Three groups of mice were treated in this experiment, 8 mice each group. DMSO group: 8 mice were injected with TRCs for 5 days and then were treated with DMSO (0.1%, vehicle) every 2 days via intravenous injection. WYC-209 0.022 mg kg⁻¹: 8 mice were injected with TRCs for 5 days then treated with WYC-209 0.022 mg kg⁻¹ every 2 days by intravenous injection. WYC-209 0.22 mg kg⁻¹: 8 mice were injected with TRCs for 5 days and then were treated with WYC-209 0.22 mg kg⁻¹ every 2 days by intravenous injection. Mice were dissected on day 30 or on the day of death to examine signs of lung metastases. b Lung metastasis frequency of B16-F1 TRCs after treated with WYC-209. ^*P < 0.05 with Fisher’s exact test. c Survival ratio of C57BL/6 mice transplanted with TRCs treated with WYC-209 or DMSO in protocol (a). Statistical analyses of survival ratio in c were performed by Mantel–Cox test (^**P < 0.01 compared to DMSO-treated group)